InSite Vision (ISV) Receives Notice of Allowance From USPTO for Patent on DuraSite® 2 Ophthalmic Drug Delivery System
7/2/2013 8:31:39 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on its DuraSite® 2 next-generation enhanced drug delivery system. DuraSite 2 provides a broad platform for developing topically delivered ocular drugs with enhanced tissue penetration in order to improve efficacy and dosing convenience. The patent is expected to provide protection to 2029 for both the delivery system and the drugs that are formulated with DuraSite 2.
Help employers find you! Check out all the jobs and post your resume.
comments powered by